Table 2 Description of cost-effectiveness study characteristics
From: Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
First Author | Year | Country | Study | Effectiveness measure | Model | Time period | Sensitity analysis | Discount rate | ICER | QALY(Y) |
|---|---|---|---|---|---|---|---|---|---|---|
Xinyan-Li | 2018 | China | Beyound | QALY,LY,Total cost,ICER | Markov | Ten-years | Yes | 3% | B + CP VS. PI + CP:$130,937.09/QALY | 1.17;0.83 |
Bhadhuri-Arjun | 2019 | Switzerland | Keynote-024 | QALY,LY,Total cost,ICER | A partitioned survival model | 20 years | Yes | 3% | Pembrolizumab(223,324 CHF) vs. chemotherapy(CHF146,264):CHF 77,060 per QALY | 3.05;1.71 |
Guoqiang liu | 2021 | China | Impower-110 | QALY,LY,Total cost,ICER | Adecision-analytic model | 10 years | Yes | 5% | Atezolizumab VS. Chemotherapy: $168,902.66/QALY | 1.31;0.90 |
Ye Peng | 2021 | USA | Impower-110 | QALY,LY,Total cost,ICER | Markov | - | Yes | 3% | Atezolizumab VS. Chemotherapy: $170,730/QALY | 2.36;1.08 |
Zhiguang Yang | 2021 | China | Impower-130 | QALY,LY,Total cost,ICER | Markov | - | Yes | 5% | Atezolizumab + Chemotherapy vs. Chemotherapy:$325,328.71 QALY | 0.87;0.68 |
Shen lin | 2020 | USA | Impower-130 | QALY,LY,Total cost,ICER | Markov | 10 years | Yes | 3% | Atezolizumab + Chemotherapy vs. Chemotherapy:$ 333,199QALY | 0.99;0.67 |
Xu H | 2020 | China | Keynote-042 | QALY,ICER | Markov; partition-survival | Yes | PembrolizumabVS.Chemotherapy(CNY244,495.54/QALY) | — | ||
Insinga-R | 2020 | Taiwan | Keynote-189 + Keynote-407 | ICER,QALY | partition-survival | 20 years | No | 3% | — | — |
Ralph.P.Insinga | 2019 | US | Keynote-407 | ICER,QALY | partition-survival | 20 years | Yes | 3% | Pembrolizumab + Chemotherapy vs. Chemotherapy:$86,293/QALY | 3.86;1.91 |
H.Loong | 2017 | Hong-Kong | Keynote-024 | ICER,QALY,Total-cost | partition-survival | 10 years | Yes | 3% | PembrolizumabVS. chemotherapy:HK$865,189(USD110,922)per QALY | 0.29(by) |
Min-Huang | 2017 | USA | Keynote-024 | QALY,LY,ICER | partition-survival | 20 years | Yes | 3% | PembrolizumabVS. chemotherapy:$US97,621per QALY | 2.60;1.55 |
Pinheiro-BA | 2017 | Portugal | Keynote-024 | QALY,LY,ICER | partition-survival | Yes | 5% | PembrolizumabVS.chemotherapy:64,205$per QALY | 1.7(by) | |
Kexun-Zhou | 2019 | China | Keynote-042 | ICER,QALY,Total-cost | Markov | 10 years | Yes | 3% | PembrolizumabVS.Chemotherapy($39,404/QALY) | 2.16;1.04 |
Min-Huang | 2019 | USA | Keynote-042 | QALY,LY,ICER | partition-survival | 20 years | Yes | 3% | PembrolizumabVS.Chemotherapy($130,155/QALY) | 1.77;1.28 |
Ralph.P.Insinga | 2018 | US | Keynote-189 | QALY,LY,Total cost,ICER | partition-survival | 20 years | Yes | 3% | Pembrolizumab + Chemotherapy vs. Chemotherapy:$104,823/QALY | 2.84;1.40 |
Chouaid,C | 2020 | France | Keynote-407 | QALY,LY,ICER | partition-survival | 10 years | Yes | 4% | Pembrolizumab + Chemotherapy vs. Chemotherapy:$116,606/QALY | 0.46(by) |
Tfayli-A | 2018 | Lebanon | Pronounce | QALY,ICER | Markov | 5 years | Yes | — | BevicizumabVS.Carboplatin + Pemetrexed | 6.6(by) |
Bernardo Goulart | 2011 | USA | E4599 | QALY,ICER,LY | Markov | 4 years | Yes | 3% | Bevicizumab + Carboplatin + Paclitaxel VS. Placebo + Carboplatin + Paclitaxel $559,609.48 | 0.66;0.53 |
P. Travis Courtney | 2021 | USA | CheckMate 227 | QALY,ICER,Total-cost, | Markov | 10 years | Yes | 3% | Nivolumab-ipilimumab VS.Chemotherapy: $401 700 per QALY | 1,68;1.18 |
Minoru-Fukuda | 2019 | Japan | LOGIK0201 | Total-cost | — | — | No | Bevacizumab + Pemetrexed(3,368,428)VS.Pemetrexed(1,522,008) | ||
Bestvina, C | 2017 | USA | Keynote-021G | Total-cost | — | — | No | Carboplatin/pemetrexed/pembrolizumab($618,889)–Carboplatin/pemetrexed($249,972) | — |